Abstract
Osteosarcoma is a group of malignant tumors with a variety of histological subtypes and biological characteristics. This type of tumor mainly affects bones and soft tissues and is commonly found in children and young people. Osteosarcoma is relatively rare among malignant tumors, but due to its characteristics of easy metastasis and poor clinical prognosis, its clinical importance cannot be ignored. This study aims to screen for Anemoside B4 drugs that target MFAP4 expression in patient-derived tumor xenografts (PDTX) of osteosarcoma to enhance personalized medicine. Patients with Osteosarcoma and normal volunteer were obtained from our hospital. All mice were inoculated with MG-63 cells by MFAP4 plasmid. The mRNA expression of MFAP4 was up - regulated in osteosarcoma patients. Single-cell RNA Sequencing (scRNA-Seq) data reveals MFAP4 expression levels in Osteoclasts of osteosarcoma model. MFAP4 promoted cancer in mice model of osteosarcoma. MFAP4 promoted cell growth of osteosarcoma through the inhibition of ferroptosis. MFAP4 reduced ROS accumulation and mitochondria-dependent ferroptosis. MFAP4 suppressed FAK signal axis in model of osteosarcoma. Screening drugs of Anemoside B4 for MFAP4 expression in osteosarcoma. Anemoside B4 reduced cancer in mice model of osteosarcoma by suppression of ferroptosis. Anemoside B4 reduced ROS accumulation and mitochondria-dependent ferroptosis by MFAP4. MFAP4 inhibits mitochondria-dependent ferroptosis in model of osteosarcoma through FAK signal axis. Anemoside B4 reduced ROS accumulation and mitochondria-dependent ferroptosis by MFAP4. Importantly, Anemoside B4 is a possible therapeutic option to relieve mitochondria-dependent ferroptosis for osteosarcoma or other cancer diseases.